Advanced search
Publication Cover
Infection and Drug Resistance Volume 14, 2021 - Issue
Submit an article Journal homepage
222
Views
4
CrossRef citations to date
0
Altmetric
Case Report

Carbapenem-Resistant Klebsiella pneumoniae Osteomyelitis Treated with Ceftazidime-Avibactam in an Infant: A Case Report

Zejuan Ji1 Department of Orthopaedic Surgery, Children’s Hospital Affiliated to Zhengzhou University, Henan Children’s Hospital, Zhengzhou Children’s Hospital, Zhengzhou, Henan, People’s Republic of ChinaCorrespondence[email protected] [email protected]
,
Keming Sun1 Department of Orthopaedic Surgery, Children’s Hospital Affiliated to Zhengzhou University, Henan Children’s Hospital, Zhengzhou Children’s Hospital, Zhengzhou, Henan, People’s Republic of China
,
Zhenwei Li1 Department of Orthopaedic Surgery, Children’s Hospital Affiliated to Zhengzhou University, Henan Children’s Hospital, Zhengzhou Children’s Hospital, Zhengzhou, Henan, People’s Republic of China
,
Weyland Cheng1 Department of Orthopaedic Surgery, Children’s Hospital Affiliated to Zhengzhou University, Henan Children’s Hospital, Zhengzhou Children’s Hospital, Zhengzhou, Henan, People’s Republic of China;2 Henan Provincial Key Laboratory of Children’s Genetics and Metabolic Diseases, Children’s Hospital Affiliated to Zhengzhou University, Henan Children’s Hospital, Zhengzhou Children’s Hospital, Zhengzhou, Henan, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-1846-2946
ORCID Icon &
Junwen Yang3 Microbiology Laboratory, Children’s Hospital Affiliated to Zhengzhou University, Henan Children’s Hospital, Zhengzhou Children’s Hospital, Zhengzhou, Henan, People’s Republic of China
Pages 3109-3113 | Published online: 11 Aug 2021

References

  • McNeilJC. Acute hematogenous osteomyelitis in children: clinical presentation and management. Infect Drug Resist. 2020;13:4459–4473. doi:10.2147/IDR.S25751733364793
  • YanJ, PuS, JiaX, et al. Multidrug resistance mechanisms of carbapenem resistant Klebsiella pneumoniae strains isolated in Chongqing, China. Ann Lab Med. 2017;37(5):398–407. doi:10.3343/alm.2017.37.5.39828643488
  • WeiJ, ZouC, WangD, HuangA, NiuS. Genetic diversity and in vitro activity of ceftazidime/avibactam and aztreonam/avibactam against imipenem-resistant Enterobacteriaceae isolates in Southwest China: a single-centre study. J Glob Antimicrob Resist. 2020;22:448–451. doi:10.1016/j.jgar.2020.04.02332387260
  • Munoz-PriceLS, PoirelL, BonomoRA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785–796. doi:10.1016/S1473-3099(13)70190-723969216
  • CaniE, MoussaviF, OcheretyanerE, SharmaR, BrownC, EilertsonB. Carbapenem-resistant Klebsiella pneumoniae vertebral osteomyelitis in a renal transplant recipient treated with ceftazidime-avibactam. Transpl Infect Dis. 2018;20(2):e12837. doi:10.1111/tid.1283729359842
  • De Leon-borrasR, Alvarez-CardonaJ, VidalJA, GuiotHM. Ceftazidime/avibactam for refractory bacteremia, vertebral diskitis/osteomyelitis with pre-vertebral abscess and bilateral psoas pyomyositis secondary to Klebsiella Pneumoniae Carbapenemase-Producing Bacteria (KPC). P R Health Sci J. 2018;37(2):128–131.29905925
  • SchimmentiA, BrunettiE, SeminariE, MarianiB, CambieriP, OrsoliniP. Prosthetic joint infection from carbapenemase-resistant Klebsiella pneumoniae successfully treated with ceftazidime-avibactam. Case Rep Infect Dis. 2018;2018:1854805.30186645
  • KohnoS, BandoH, YoneyamaF, et al. The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: a multicenter, open-label, noncomparative phase 3 study. J Infect Chemother. 2021;27(2):262–270. doi:10.1016/j.jiac.2020.09.03233191112
  • YangTY, HsiehYJ, KaoLT, et al. Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan. J Microbiol Immunol Infect. 2021. doi:10.1016/j.jmii.2021.02.001
  • PrasadP, SunJ, DannerRL, NatansonC. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54(12):1699–1709. doi:10.1093/cid/cis27022467668
  • LiangQ, HuangM, XuZ. Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Braz J Infect Dis. 2019;23(1):60–65. doi:10.1016/j.bjid.2018.12.00430796888
  • ThomasR, VelaphiS, EllisS, et al. The use of polymyxins to treat carbapenem resistant infections in neonates and children. Expert Opin Pharmacother. 2019;20(4):415–422. doi:10.1080/14656566.2018.155981730576264
  • MessinaAF, NamtuK, GuildM, DumoisJA, BermanDM. Trimethoprim-sulfamethoxazole therapy for children with acute osteomyelitis. Pediatr Infect Dis J. 2011;30(12):1019–1021. doi:10.1097/INF.0b013e31822db65821817950
  • PezoneI, LeoneS. Role of Trimethoprim-sulfamethoxazole for treatment of acute osteomyelitis in children. Pediatr Infect Dis J. 2012;31(6):660–661;author reply 661. doi:10.1097/INF.0b013e318255ff8d
  • IosifidisE, ChorafaE, AgakidouE, et al. Use of Ceftazidime-avibactam for the treatment of extensively drug-resistant or pan drug-resistant Klebsiella pneumoniae in neonates and children <5 years of age. Pediatr Infect Dis J. 2019;38(8):812–815.31135647
  • ZhouJ, YangJ, HuF, GaoK, SunJ, YangJ. Clinical and molecular epidemiologic characteristics of ceftazidime/avibactam-resistant carbapenem-resistant Klebsiella pneumoniae in a neonatal intensive care unit in China. Infect Drug Resist. 2020;13:2571–2578. doi:10.2147/IDR.S25692232801794

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.